NASDAQ:PGNX - Progenics Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.91 +0.07 (+1.45 %)
(As of 01/20/2019 04:00 PM ET)
Previous Close$4.91
Today's Range$4.7846 - $4.98
52-Week Range$3.62 - $9.42
Volume688,917 shs
Average Volume1.26 million shs
Market Capitalization$415.11 million
P/E Ratio-5.46
Dividend YieldN/A
Beta2.57
Progenics Pharmaceuticals, Inc. develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer; PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in pre-clinical stage for treatment of metastatic prostate cancer; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness adult patients receiving palliative care when laxative therapy has not been sufficient; and Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.

Receive PGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for PGNX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:PGNX
CUSIP74318710
Phone646-975-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$11.70 million
Book Value$0.90 per share

Profitability

Net Income$-51,010,000.00
Net Margins-341.78%

Miscellaneous

Employees64
Market Cap$415.11 million
OptionableOptionable

Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions

What is Progenics Pharmaceuticals' stock symbol?

Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."

How were Progenics Pharmaceuticals' earnings last quarter?

Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) released its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.09) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.18) by $0.09. The biotechnology company earned $5.32 million during the quarter, compared to analysts' expectations of $4.14 million. Progenics Pharmaceuticals had a negative return on equity of 66.86% and a negative net margin of 341.78%. View Progenics Pharmaceuticals' Earnings History.

When is Progenics Pharmaceuticals' next earnings date?

Progenics Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Progenics Pharmaceuticals.

What price target have analysts set for PGNX?

4 brokerages have issued twelve-month target prices for Progenics Pharmaceuticals' stock. Their forecasts range from $6.50 to $15.00. On average, they expect Progenics Pharmaceuticals' stock price to reach $11.6250 in the next twelve months. This suggests a possible upside of 136.8% from the stock's current price. View Analyst Price Targets for Progenics Pharmaceuticals.

What is the consensus analysts' recommendation for Progenics Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Progenics Pharmaceuticals.

What are Wall Street analysts saying about Progenics Pharmaceuticals stock?

Here are some recent quotes from research analysts about Progenics Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. " (1/19/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We maintain an Overweight rating and 12-month PT of $15 on the shares of PGNX. Although we like the rare disease opportunity for AZEDRA (PDUFA 7/30), we also like the PSMA-targeted pipeline for prostate cancer. Moreover, what we have come to appreciate in the PGNX story is the optionality of the pipeline, which extends to the potential for out-licensing, financing and clinical development." (5/20/2018)

Has Progenics Pharmaceuticals been receiving favorable news coverage?

News stories about PGNX stock have trended neutral recently, according to InfoTrie Sentiment. The research firm identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Progenics Pharmaceuticals earned a news sentiment score of 0.1 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the immediate future.

Who are some of Progenics Pharmaceuticals' key competitors?

Who are Progenics Pharmaceuticals' key executives?

Progenics Pharmaceuticals' management team includes the folowing people:
  • Mr. Mark R. Baker, CEO & Director (Age 64)
  • Mr. Patrick Fabbio, Sr. VP, CFO & Principal Accounting Officer (Age 51)
  • Dr. Vivien Wong, Exec. VP of Devel. (Age 62)
  • Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 46)
  • Melissa Downs, Sr. Mang. of Investor Relations

Who are Progenics Pharmaceuticals' major shareholders?

Progenics Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Louisiana State Employees Retirement System (0.04%) and Boston Advisors LLC (0.02%). View Institutional Ownership Trends for Progenics Pharmaceuticals.

Which major investors are selling Progenics Pharmaceuticals stock?

PGNX stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System. View Insider Buying and Selling for Progenics Pharmaceuticals.

Which major investors are buying Progenics Pharmaceuticals stock?

PGNX stock was purchased by a variety of institutional investors in the last quarter, including Boston Advisors LLC. View Insider Buying and Selling for Progenics Pharmaceuticals.

How do I buy shares of Progenics Pharmaceuticals?

Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Progenics Pharmaceuticals' stock price today?

One share of PGNX stock can currently be purchased for approximately $4.91.

How big of a company is Progenics Pharmaceuticals?

Progenics Pharmaceuticals has a market capitalization of $415.11 million and generates $11.70 million in revenue each year. The biotechnology company earns $-51,010,000.00 in net income (profit) each year or ($0.90) on an earnings per share basis. Progenics Pharmaceuticals employs 64 workers across the globe.

What is Progenics Pharmaceuticals' official website?

The official website for Progenics Pharmaceuticals is http://www.progenics.com.

How can I contact Progenics Pharmaceuticals?

Progenics Pharmaceuticals' mailing address is 285 FULTON STREET 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]


MarketBeat Community Rating for Progenics Pharmaceuticals (NASDAQ PGNX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  322 (Vote Outperform)
Underperform Votes:  268 (Vote Underperform)
Total Votes:  590
MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe PGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/20/2019 by MarketBeat.com Staff

Featured Article: Reverse Stock Split

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel